NEW YORK, NY / ACCESSWIRE / October 8, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
International Flavors & Fragrances Inc. (NYSE:IFF)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/international-flavors-fragrances-inc-loss-submission-form?prid=3864&wire=1
Lead Plaintiff Deadline: October 11, 2019
Class Period: May 7, 2018 to August 5, 2019
Allegations against IFF include that: (1) Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) senior management at Frutarom were aware of such improper payments; (3) as a result, Frutarom's financial results were materially overstated; (4) as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) the Company had not completed adequate due diligence before acquiring Frutarom; (6) as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Altria Group, Inc. (NYSE:MO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/altria-group-inc-loss-submission-form?prid=3864&wire=1
Lead Plaintiff Deadline: December 2, 2019
Class Period: December 20, 2018 to September 24, 2019
Allegations against MO include that: (i) Altria had conducted insufficient due diligence into JUUL prior to the Company's $12.8 billion investment, or 35% stake, in JUUL; (ii) Altria consequently failed to inform investors, or account for, material risks associated with JUUL's products and marketing practices, and the true value of JUUL and its products; (iii) all of the foregoing, as well as mounting public scrutiny, negative publicity, and governmental pressure on e-vapor products and JUUL made it reasonably likely that Altria's investment in JUUL would have a material negative impact on the Company's reputation and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Myriad Genetics, Inc. (NASDAQ:MYGN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/myriad-genetics-inc-loss-submission-form?prid=3864&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: September 2, 2016 to August 13, 2019
Allegations against MYGN include that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong